Chronic psychological stress has long been suspected to accelerate biological aging, but the molecular machinery connecting them has remained elusive. A newly proposed mechanistic axis centered on corticotropin-releasing factor — the brain's primary stress-signaling neuropeptide — offers a compelling framework that could reshape how scientists and clinicians think about stress-related age acceleration and neurodegeneration.
This review, published in Frontiers in Aging Neuroscience, synthesizes preclinical evidence to construct a four-stage cascade: CRF signaling, primarily through its type 1 receptor (CRFR1), disrupts mitochondrial dynamics and suppresses biogenesis, leading to an overproduction of reactive oxygen species and mitochondrial DNA damage. The compromised mitochondria then release damage-associated molecular patterns (DAMPs), which activate innate immune pathways. The result is a smoldering, chronic low-grade inflammation — a state increasingly known as "inflammaging" — that ultimately promotes cellular senescence. The type 2 receptor, CRFR2, appears to counterbalance these effects, suggesting a receptor-specific therapeutic window.
This framework is notable because it mechanistically links neuroendocrine stress physiology to two of the most well-established hallmarks of aging: mitochondrial dysfunction and chronic inflammation. The CRF system has been studied for decades primarily in the context of anxiety and HPA-axis dysregulation, but positioning it as a master regulator of stress-accelerated aging is a meaningful conceptual advance. However, several limitations warrant caution. The evidence base is largely preclinical, relying on animal models where CRF overexpression or receptor manipulation produces accelerated aging phenotypes; direct human causal evidence remains thin. Additionally, this is a review article rather than original empirical research, meaning the proposed axis is an integrative theoretical model rather than a tested intervention target. Nevertheless, the CRFR1/CRFR2 receptor dichotomy offers a tractable pharmacological entry point, and existing CRFR1 antagonists already in clinical development for depression and anxiety could feasibly be evaluated in aging contexts. For longevity researchers, this model elevates chronic stress management from a lifestyle recommendation to a molecularly grounded biological imperative.
